Quebec Lung Cancer Screening PLUS Trial

Launched by NICOLE EZER, MD, FRCPC, MPH · Jun 30, 2022

Keywords

ClinConnect Summary

The Quebec Lung Cancer Screening PLUS Trial is studying whether an educational program can help patients with untreated Chronic Obstructive Pulmonary Disease (COPD) and certain heart conditions stick to their prescribed medications. This program is being offered to people who are already participating in a lung cancer screening using a low-dose CT scan. The goal is to see if providing extra information and support can lead to better adherence to medication guidelines over a period of 12 months.

To be eligible for this trial, participants must have been screened for lung cancer and have mild to severe coronary artery calcification (a sign of heart disease) without being on recommended cholesterol-lowering medication. They should also have a diagnosis of COPD and be experiencing symptoms but not currently receiving first-line treatment for it. The trial is open to individuals of all genders aged between 20 and 70. If you qualify and choose to participate, you will receive education and support to help you manage your health better. It's important to note that those with a high suspicion of lung cancer or serious heart issues won't be able to join the study, as this isn't the right time to start new treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstration project by low dose CT scan of the chest.
• • Cardiovascular aim: mild to severe CAC identified on low dose CT, not on guideline recommended lipid-lowering therapy.
• • COPD aim: diagnosed with COPD, symptomatic (mMRC \>=1 or CAT\>= 10) and untreated, or not on first line guideline recommended therapy for COPD.
• Exclusion Criteria:
• • Any participant with a high suspicion of lung cancer, defined as Lung-RADS (Lung Imaging Reporting and Data System) 3 or 4, as this is an inopportune time to initiate new medical therapies.
• • Cardiovascular aim: Absent CAC, known clinical atherosclerosis, known former heart surgery, Diabetes Mellitus.
• • COPD aim: asymptomatic, or already on appropriate first line COPD therapy.